RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS Omeclamox-Pak In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the products FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberlands payments of royalties and manufacturing fees to GEL. The Company has now assumed responsibility for the maintenance of the products FDA approval and for the oversight of the products manufacturing and packaging. Vibativ During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results. Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes. Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product. The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. The following table summarizes the initial payments and consideration for the business combination: Consideration: Cash paid at closing $ 20,000,000 Cash payment during early 2019 5,000,000 Fair value of contingent consideration - net sales royalty 9,182,000 Total consideration $ 34,182,000 The contingent consideration liability represents the future net sales royalty payments discussed above. Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs. As a result, the valuations are classified as Level 3 fair value measurements. The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly. Contingent consideration liability Balance at November 12, 2018 $ 9,034,000 Change in fair value of contingent consideration included in operating expenses (40,000) Contingent consideration earned and accrued in operating expenses 508,000 Balance at December 31, 2018 9,502,000 Adjustment to initial fair value of the contingent consideration liability 148,000 Cash payment of royalty during the period (908,347) Change in fair value of contingent consideration included in operating expenses (681,577) Contingent consideration earned and accrued in operating expenses 560,128 Balance at September 30, 2019 $ 8,620,204 The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ: Finished goods inventory $ 6,624,000 Work in process - unlabeled vials 3,970,000 Work in process - validation vials 1,827,000 Raw materials 9,129,000 Total inventory $ 21,550,000 Intellectual property amortizable intangible assets 11,750,000 Goodwill 882,000 Total intangibles and goodwill 12,632,000 Total assets acquired $ 34,182,000 The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.2 million and the non-current portion is $6.4 million. Ethyol and Totect During May 2019, Cumberland entered into a Dissolution Agreement with Clinigen Healthcare Limited ("Agreement") in which the Company will return the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Agreement originally resulted in a transition from the Company's current arrangement with Clinigen effective September 30, 2019. In early September 2019, Clinigen and Cumberland completed an Amendment to the Agreement whereby the transition date was changed to late December 2019. Under the terms of the agreement, Cumberland will no longer be involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products. In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5 million in financial consideration paid over the two-years following the transition date.